S&P upgrades Novo Nordisk

Standard & Poor's said it raised the long-term corporate credit rating on Novo Nordisk A/S to A+ from A.

The A-1 short-term rating was affirmed.

The outlook is stable.

The upgrade reflects Novo Nordisk's continued ability to achieve significant above-industry growth in its core activities and to maintain world-leading positions as a provider of insulin and diabetes medications, S&P said.

The ratings also consider a perception of management's ongoing conservative financial policy in a consolidating industry, the agency said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.